Equities analysts expect that Evoke Pharma Inc (NASDAQ:EVOK) will announce earnings of ($0.22) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Evoke Pharma’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.18). Evoke Pharma posted earnings of ($0.18) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 22.2%. The firm is scheduled to announce its next earnings results on Wednesday, March 21st.

On average, analysts expect that Evoke Pharma will report full-year earnings of ($1.00) per share for the current financial year, with EPS estimates ranging from ($1.03) to ($0.96). For the next fiscal year, analysts forecast that the business will report earnings of $0.09 per share, with EPS estimates ranging from ($0.54) to $1.16. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.13). During the same period last year, the company earned ($0.29) EPS.

A number of research firms have recently commented on EVOK. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Evoke Pharma in a report on Monday, September 18th. B. Riley reissued a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a report on Wednesday, November 15th. Zacks Investment Research cut shares of Evoke Pharma from a “hold” rating to a “sell” rating in a report on Friday, December 1st. FBR & Co reissued a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a report on Monday, October 30th. Finally, ValuEngine cut shares of Evoke Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $9.00.

Evoke Pharma (EVOK) opened at $2.31 on Tuesday. The company has a market cap of $35.60, a PE ratio of -2.26 and a beta of 1.09. Evoke Pharma has a fifty-two week low of $1.87 and a fifty-two week high of $4.55.

An institutional investor recently raised its position in Evoke Pharma stock. Sphera Funds Management LTD. raised its position in shares of Evoke Pharma Inc (NASDAQ:EVOK) by 14.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 571,022 shares of the specialty pharmaceutical company’s stock after purchasing an additional 71,022 shares during the quarter. Sphera Funds Management LTD. owned approximately 3.71% of Evoke Pharma worth $1,907,000 at the end of the most recent quarter. 13.64% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/26/analysts-anticipate-evoke-pharma-inc-evok-to-announce-0-22-eps.html.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.